Queipo Zaragozá José Antonio, Chicote Pérez Francisco, Beltrán Meseguer Juan Francisco, Borrell Palanca Alberto, Giner Marco Vicente, Esteve Claramunt Jesús, Pastor Sempere Francisco
Servicio de Urología, Hospital de Sagunto, Valencia, España.
Arch Esp Urol. 2004 Jan-Feb;57(1):35-40.
Anemia is a frequent finding in patients with prostate cancer. Reduction of erythropoiesis caused by androgenic blockade is among its etiologies. Therefore, quality of life of these patients results decreased, being origin of significant morbidity and mortality. Recombinant forms of human erythropoietin have demonstrated their effectiveness improving quality of life of patients with various solid tumors, but specific studies in prostate cancer are a few. Our objective is to evaluate the efficacy of human recombinant erythropoietin (EPO) correcting anemia and improving the quality of life of patients with prostate cancer.
Prospective study of patients with prostate cancer under combined androgenic blockade treatment having hemoglobin levels lower than 11 g/dl. We analyze clinical characteristics and quality of life prior to EPO dispense. We used the Triple Linear Analogical Scale for patients with cancer (CLAS) to evaluate quality of life. EPO was administered during 12 weeks (10.000 units subcutaneously, three times a week). We study the evolution of different parameters compared to baseline.
We included a total of 17 patients. Average age was 75.5 +/- 5.9 yr. Average time of neoplasia evolution was 57.6 +/- 13.9 months. Eleven patients presented active disease (PSA > 1 ng/ml). Mean initial haemoglobin level was 10.3 +/- 0.4 mg/dl, reaching 12.2 +/ - 1.0 after treatment (p < 0.001). Patients with active disease and levels of initial haemoglobin smaller than 10.2 g/dl presented worse outcomes. There were not adverse events attributable to EPO.
We consider that the administration of EPO increases significantly the levels of haemoglobin and the quality of life of patients with prostate adenocarcinoma, being the response worse in patients with low levels of baseline haemoglobin.
贫血在前列腺癌患者中很常见。雄激素阻断导致的红细胞生成减少是其病因之一。因此，这些患者的生活质量下降，成为严重发病和死亡的根源。重组人促红细胞生成素已证明其对改善各种实体瘤患者生活质量的有效性，但针对前列腺癌的具体研究较少。我们的目的是评估重组人促红细胞生成素（EPO）纠正前列腺癌患者贫血并改善其生活质量的疗效。
对接受联合雄激素阻断治疗且血红蛋白水平低于11 g/dl的前列腺癌患者进行前瞻性研究。我们分析了给予EPO之前的临床特征和生活质量。我们使用癌症患者三线类比量表（CLAS）来评估生活质量。EPO给药12周（皮下注射10000单位，每周三次）。我们研究了与基线相比不同参数的变化情况。
我们共纳入了17例患者。平均年龄为75.5±5.9岁。肿瘤平均进展时间为57.6±13.9个月。11例患者疾病处于活动期（前列腺特异抗原>1 ng/ml）。初始平均血红蛋白水平为10.3±0.4 mg/dl，治疗后达到12.2±1.0（p<0.001）。疾病处于活动期且初始血红蛋白水平低于10.2 g/dl的患者预后较差。没有可归因于EPO的不良事件。
我们认为，给予EPO可显著提高前列腺腺癌患者的血红蛋白水平和生活质量，基线血红蛋白水平较低的患者反应较差。
